<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高解释</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id = 1vuepj4z_tesaaxkwjxbogotaabxd6u-nvu8003krcpqppqpqpq8ylq c8 ylqc-cc-cc-cc = 20220230708114040404.unight -2＆ff = 20250415061254＆utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8LYLQCC-＆utm_MEDIUM = RSS＆v = 2.18.0.post9+e462414＆utce = 2.18.0.post9+e462414＆utce =<description>心血管高额外版：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20250415061254&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期二，2025年4月15日10:12:56 +0000</lastbuilddate><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>心脏肥大中蛋白质的翻译后酰化</title><link/>https://pubmed.ncbi.nlm.nih.gov/40229510/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>酰基化是翻译后修饰，其中官能团在蛋白质上附着在氨基酸上。大多数酰基化（乙酰化，丁基化，链氨基化，lactylation，malonylation，丙酰化和琥珀酰化）涉及赖氨酸，但半胱氨酸（棕榈酰化）和甘氨酸（肉豆蔻酰化）保留也可以改变。酰基化在物理和病理生理过程中具有重要作用，包括心脏肥大和相关心血管疾病。这些... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。 2025年4月14日。DOI：10.1038/S41569-025-01150-1。在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">酰基化是翻译后修饰，其中官能团在蛋白质上附着在氨基酸上。大多数酰基化（乙酰化，丁基化，链氨基化，lactylation，malonylation，丙酰化和琥珀酰化）涉及赖氨酸，但半胱氨酸（棕榈酰化）和甘氨酸（肉豆蔻酰化）保留也可以改变。酰基化在物理和病理生理过程中具有重要作用，包括心脏肥大和相关心血管疾病。这些翻译后修饰会影响染色质结构，转录调节和代谢途径，从而影响心肌细胞功能和病理。这些乙酰基转移酶，组蛋白脱乙酰基酶和Sirtuins之间的动态相互作用强调了细胞稳态和病理过程的复杂性。新兴的证据强调了靶向酰基化来调节酶活性和代谢物水平的治疗潜力，从而提供了新治疗的希望。在这篇综述中，我们探讨了酰基化的潜力机制，这些机制通过这些机制有助于心脏肥大，突出了该调节网络中的复杂性和潜在的治疗靶标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40229510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40229510</a> | doi： <a href=https://doi.org/10.1038/s41569-025-01150-1>10.1038/s41569-025-01150-1</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40229510</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Ying-QI Liu</dc:creator><dc:creator>秦阳</dc:creator><dc:creator>Guo-Wei他</dc:creator><dc:date>2025-04-14</dc:date><dc:source>自然评论。心脏病学</dc:source><dc:title>心脏肥大中蛋白质的翻译后酰化</dc:title><dc:identifier>PMID：40229510</dc:identifier><dc:identifier> doi：10.1038/s41569-025-01150-1</dc:identifier></item><item><title>扩大半紫杉酸盐的心血管指示：灵魂和大步试验的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/40229511/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。 2025年4月14日。DOI：10.1038/S41569-025-01158-7。在线印刷。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40229511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40229511</a> | doi： <a href=https://doi.org/10.1038/s41569-025-01158-7>10.1038/s41569-025-01158-7</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40229511</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Karina Huynh</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>自然评论。心脏病学</dc:source><dc:title>扩大半紫杉酸盐的心血管指示：灵魂和大步试验的结果</dc:title><dc:identifier>PMID：40229511</dc:identifier><dc:identifier> doi：10.1038/s41569-025-01158-7</dc:identifier></item><item><title>评估心律失常消融的逆行和反式方法的后果</title><link/>https://pubmed.ncbi.nlm.nih.gov/40228071/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。 2025年4月15日； 151（15）：1060-1062。 doi：10.1161/CirculationAha.125.073626。 EPUB 2025 4月14日。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40228071/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40228071</a> | doi： <a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073626>10.1161/CirculationAha.125.073626</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40228071</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>尼古拉斯·诺西卡（Nikolas Nozica）</dc:creator><dc:creator> Usha Tedrow</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>循环</dc:source><dc:title>评估心律失常消融的逆行和反式方法的后果</dc:title><dc:identifier>PMID：40228071</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.125.073626</dc:identifier></item><item><title>校正：进展轨迹的单细胞重建揭示了病理心肥大的干预原则</title><link/>https://pubmed.ncbi.nlm.nih.gov/40228070/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。 2025年4月15日； 151（15）：E956。 doi：10.1161/cir.00000000001333。 EPUB 2025 4月14日。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40228070/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40228070</a> | doi： <a href=https://doi.org/10.1161/CIR.0000000000001333>10.1161/cir.000000001333</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40228070</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Zongna Ren</dc:creator><dc:creator>彭</dc:creator><dc:creator>丹丹·李</dc:creator><dc:creator>李李</dc:creator><dc:creator>Yingnan Liao</dc:creator><dc:creator>杨王</dc:creator><dc:creator>bingying周</dc:creator><dc:creator>李王</dc:creator><dc:date>2025-04-14</dc:date><dc:source>循环</dc:source><dc:title>校正：进展轨迹的单细胞重建揭示了病理心肥大的干预原则</dc:title><dc:identifier>PMID：40228070</dc:identifier><dc:identifier> doi：10.1161/cir.000000001333</dc:identifier></item><item><title>重新编程的平滑肌细胞进行血管修复：愈合缺血组织的新途径</title><link/>https://pubmed.ncbi.nlm.nih.gov/40228069/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。 2025年4月15日； 151（15）：1095-1097。 doi：10.1161/CirculationAha.124.072958。 EPUB 2025 4月14日。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40228069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40228069</a> | doi： <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072958>10.1161/CirculationAha.124.072958</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40228069</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>李梁</dc:creator><dc:date>2025-04-14</dc:date><dc:source>循环</dc:source><dc:title>重新编程的平滑肌细胞进行血管修复：愈合缺血组织的新途径</dc:title><dc:identifier>PMID：40228069</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072958</dc:identifier></item><item><title> Peigh等人对文章的信件的回应：“心脏植入电子设备患者的房颤负担和死亡率的关联”</title><link/> https://pubmed.ncbi.nlm.nih.gov/40228068/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。 2025年4月15日； 151（15）：E925。 doi：10.1161/CirculationAha.124.072692。 EPUB 2025 4月14日。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40228068/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40228068</a> | doi： <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072692>10.1161/CirculationAha.124.072692</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40228068</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>格雷厄姆·皮格（Graham Peigh）</dc:creator><dc:creator>莎拉·卡塞马斯（Sarah C Rosemas）</dc:creator><dc:creator>安东尼我罗伯茨</dc:creator><dc:creator>Colleen Longacre</dc:creator><dc:creator>罗德·帕斯曼（Rod S Passman）</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>循环</dc:source><dc:title>Peigh等人对文章的信件的回应：“心脏植入电子设备患者的房颤负担和死亡率的关联”</dc:title><dc:identifier> PMID：40228068</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072692</dc:identifier></item><item><title> G蛋白偶联的雌激素受体1和妊娠赋予对年长女性高血压的保护</title><link/>https://pubmed.ncbi.nlm.nih.gov/40228067/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。 2025年4月15日； 151（15）：1126-1129。 doi：10.1161/CirculationAha.124.073693。 EPUB 2025 4月14日。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40228067/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40228067</a> | doi： <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073693>10.1161/CirculationAha.124.073693</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40228067</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>拉夫纳特·辛格（Ravneet Singh）</dc:creator><dc:creator> supaporn kulthinee</dc:creator><dc:creator>维多利亚·纳斯基（Victoria L NASCI）</dc:creator><dc:creator>猫王Akwo</dc:creator><dc:creator> Chibundu Juliet Umunna</dc:creator><dc:creator> Rawan N Almutlaq</dc:creator><dc:creator> Oleh M Pochynyuk</dc:creator><dc:creator>卡西安·罗宾逊·科恩（Cassianne Robinson-Cohen）</dc:creator><dc:creator> Eman Y Gohar</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>循环</dc:source><dc:title>G蛋白偶联的雌激素受体1和妊娠赋予对年长女性高血压的保护</dc:title><dc:identifier>PMID：40228067</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.073693</dc:identifier></item><item><title>偶然体育锻炼对心血管事件和死亡率的剂量反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/40228066/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>结论：以剂量反应方式，任何每日IPA量的剧烈或中等强度都与CVD风险较低有关。 Lipa与所有结果的关联较弱。一分钟的剧烈或≈3.0至3.5分钟的中等IPA与CVD较低程度相似。我们的发现突出了偶然体育锻炼的潜在心血管健康价值，尤其是对于那些难以进行结构化运动的人。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。 2025年4月15日； 151（15）：1063-1075。 doi：10.1161/CirculationAha.124.072253。 EPUB 2025 4月14日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：很少有中年和老年人进行定期休闲时间运动。偶然的体育锻炼（IPA）包括休闲时间域外日常生活的活动。没有剂量反应研究可指导以IPA为重点的干预措施和指南。我们研究了设备评估的IPA强度（剧烈[VIPA]，中度[MIPA]，Light [Lipa]）与主要不良心血管事件（MACE）和死亡率的关联，我们估计了LIPA和MIPA在VIPA 1分钟的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用前瞻性队列设计分析了2013年至2015年英国生物库的24139名非Xerter仪，平均值±SD年龄为61.9±7.6岁。 IPA能量消耗和VIPA，MIPA和LIPA的每日持续时间是通过经过验证的基于机器学习的强度分类器计算的。狼牙棒包括事件中风，心肌梗塞和心力衰竭； CVD死亡； CVD死亡率；和全因死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：分析包括22个107（MACE），22 174（CVD死亡率）和24 139（全因死亡率）参与者，对应于908/223/1071在7。9年的随访中。 IPA体积与nadir的L形相关性在≈35至38 kj·kg <sup>-1</sup> ·D <sup>-1</sup>时表现出，对应于MACE的0.49（95％CI，0.39-0.61）的危险比为0.33（CI，0.22-0.52），用于CVD的0.22-0.52）。死亡率。任何数量的VIPA或MIPA都与较低的风险相关，平原为每天约14分钟（VIPA），每天34至50分钟（MIPA）。中位VIPA（4.6分钟/d）和MIPA（23.8 min/d）持续时间与CVD死亡率危险比分别为0.62（95％CI，0.46-0.83）和0.50（95％CI，0.31-0.80）。 LIPA显示出微妙的反向梯度，对于每天>; 130分钟的水平，对于CVD死亡率具有统计学意义。一分钟的VIPA等于2.8（MACE）至3.4（CVD死亡率）MIPA和34.7（CVD死亡率）至48.5（MACE）LIPA分钟。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：以剂量反应方式，任何每日IPA量的剧烈或中等强度都与CVD风险较低有关。 Lipa与所有结果的关联较弱。一分钟的剧烈或≈3.0至3.5分钟的中等IPA与CVD较低程度相似。我们的发现突出了偶然体育锻炼的潜在心血管健康价值，尤其是对于那些难以进行结构化运动的人。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40228066/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40228066</a> | doi： <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072253>10.1161/CirculationAha.124.072253</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40228066</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Emmanuel Stamatakas</dc:creator><dc:creator> Raaj K Biswas</dc:creator><dc:creator>尼古拉斯（Nicholas a Koemel）</dc:creator><dc:creator>安吉洛·萨巴格（Angelo Sabag）</dc:creator><dc:creator>理查德·普尔斯福德（Richard Pulsford）</dc:creator><dc:creator>安德鲁·阿特金（Andrew J Atkin）</dc:creator><dc:creator> Afroditi Stathi</dc:creator><dc:creator>索尼亚·郑</dc:creator><dc:creator>CecilieThøgersen-ntoumani</dc:creator><dc:creator>乔安娜·M·布洛奇特（Joanna M Blodgett）</dc:creator><dc:creator>阿德里安·鲍曼（Adrian Bauman）</dc:creator><dc:creator> Carlos Celis-Morales</dc:creator><dc:creator>马克·哈默</dc:creator><dc:creator>杰森·吉尔先生</dc:creator><dc:creator>马修·艾哈迈迪（Matthew N Ahmadi）</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>循环</dc:source><dc:title>偶然体育锻炼对心血管事件和死亡率的剂量反应</dc:title><dc:identifier>PMID：40228066</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072253</dc:identifier></item><item><title>患者报告的结果是心力衰竭试验的终点</title><link/>https://pubmed.ncbi.nlm.nih.gov/40228065/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>心力衰竭是日益增长的医疗保健问题，影响了全球数千万个人。尽管传统的治疗策略旨在降低住院和死亡率的风险，但越来越多地认识到心力衰竭患者中患者报告的预后（PRO）的重要性。监管机构考虑了对药物和设备评估的专业人士，专业社会指南可能建议采取改善专业人士的干预措施。然而，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。 2025年4月15日； 151（15）：1111-1125。 doi：10.1161/CirculationAha.124.072158。 EPUB 2025 4月14日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心力衰竭是日益增长的医疗保健问题，影响了全球数千万个人。尽管传统的治疗策略旨在降低住院和死亡率的风险，但越来越多地认识到心力衰竭患者中患者报告的预后（PRO）的重要性。监管机构考虑了对药物和设备评估的专业人士，专业社会指南可能建议采取改善专业人士的干预措施。但是，由于几个原因，目前很难解释干预措施对心力衰竭试验中报告的PRO的影响。关于Pro评估的时间和频率尚无共识。此外，很难建立最小的临床重要差异，即对患者有意义的Pro分数的最小变化。此外，传统的分析和报告专业人士的方法，例如跨组平均差异的比较或响应者分析的比较，易于统计工件和失误。本文对这些问题进行了深入的讨论，堪萨斯城心肌病态调查表作为一个例子，以促进在心力衰竭研究，监管和临床环境中使用专业人士。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40228065/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40228065</a> | doi： <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072158>10.1161/CirculationAha.124.072158</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40228065</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Javed Butler</dc:creator><dc:creator>穆罕默德·萨里克·乌斯曼（Muhammad Shariq Usman）</dc:creator><dc:creator> Charu Gandotra</dc:creator><dc:creator>阿里·萨尔曼（Ali Salman）</dc:creator><dc:creator>安德鲁·法布（Andrew Farb）</dc:creator><dc:creator> Aliza M Thompson</dc:creator><dc:creator>诺曼·斯托克布里奇</dc:creator><dc:creator>Cordula Zeller</dc:creator><dc:creator> Folke Folkvaljon</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>循环</dc:source><dc:title>患者报告的结果是心力衰竭试验的终点</dc:title><dc:identifier>PMID：40228065</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072158</dc:identifier></item><item><title> Lu等人的信相关文章，“心脏植入电子设备患者的房颤负担和死亡率的关联”</title><link/> https://pubmed.ncbi.nlm.nih.gov/40228064/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。 2025年4月15日； 151（15）：E923-E924。 doi：10.1161/CirculationAha.124.071418。 EPUB 2025 4月14日。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40228064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40228064</a> | doi： <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071418>10.1161/CirculationAha.124.071418</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40228064</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>小卢</dc:creator><dc:creator>Shaowen Liu</dc:creator><dc:creator> Songwen Chen</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>循环</dc:source><dc:title>Lu等人的信相关文章，“心脏植入电子设备患者的房颤负担和死亡率的关联”</dc:title><dc:identifier> PMID：40228064</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.071418</dc:identifier></item><item><title>拟南芥单核图谱解码叶子的感应和营养分配</title><link/>https://pubmed.ncbi.nlm.nih.gov/40220755/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>随着单细胞RNA测序（SCRNA-SEQ）技术的快速进步，探索关键物理过程的系统性协调已经进入了一个新时代。在这里，我们使用超过100万个核能从20个组织中产生了一个全面的拟南芥转录组图集，这些组织包括多个发育阶段。我们的分析确定了在以前的单特性研究中尚未表征的细胞类型，并揭示了细胞类型的保护和... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>。 2025年4月10日：S0092-8674（25）00297-1。 doi：10.1016/j.cell.2025.03.024。在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">随着单细胞RNA测序（SCRNA-SEQ）技术的快速进步，探索关键物理过程的系统性协调已经进入了一个新时代。在这里，我们使用超过100万个核能从20个组织中产生了一个全面的拟南芥转录组图集，这些组织包括多个发育阶段。我们的分析确定了在以前的单特性研究中尚未表征的细胞类型，并揭示了不同器官之间的细胞类型保存和特异性。通过时间分辨的采样，我们揭示了主要叶片细胞类型之间高度协调的发作和敏感性的进展。我们最初制定了两个分子指数，以量化单细胞分辨率的叶片细胞的衰老状态。此外，在加权基因共表达网络分析的支持下，我们确定了数百个可能综合调节叶片感应的正面集线器基因。受确定的枢纽基因的功能验证的启发，我们在不同的细胞类型之间从源叶到下沉的组织中构建了碳和氮分配的系统性方案。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40220755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40220755</a> | doi： <a href=https://doi.org/10.1016/j.cell.2025.03.024>10.1016/j.cell.2025.03.024</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40220755</guid><pubDate> Sat, 12 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Xing Guo</dc:creator><dc:creator> Yichuan Wang</dc:creator><dc:creator> Caiyao Zhao</dc:creator><dc:creator>谭</dc:creator><dc:creator>魏yan</dc:creator><dc:creator> Sunhuan Xiang</dc:creator><dc:creator>丹张</dc:creator><dc:creator>张张</dc:creator><dc:creator>Menging Zhang</dc:creator><dc:creator>杨阳</dc:creator><dc:creator>孟Yan</dc:creator><dc:creator> Pingli Xie</dc:creator><dc:creator> Yi Wang</dc:creator><dc:creator>李</dc:creator><dc:creator>东牙</dc:creator><dc:creator>Xuanmin guang</dc:creator><dc:creator>温文·肖</dc:creator><dc:creator>方王</dc:creator><dc:creator>Haoxuan Wang</dc:creator><dc:creator> Sunil Kumar Sahu</dc:creator><dc:creator> Min Liu</dc:creator><dc:creator> Tong Wei</dc:creator><dc:creator>杨彭</dc:creator><dc:creator>是的Qiu</dc:creator><dc:creator>陶彭</dc:creator><dc:creator>Yi Zhang</dc:creator><dc:creator> Xuemei ni</dc:creator><dc:creator> Zhicheng Xu</dc:creator><dc:creator> Haorong Lu</dc:creator><dc:creator>李海李</dc:creator><dc:creator>阳阳</dc:creator><dc:creator>Ertao Wang</dc:creator><dc:creator>迈克尔·利斯比</dc:creator><dc:creator>Huan Liu</dc:creator><dc:creator> Hongwei Guo</dc:creator><dc:creator> Xun Xu</dc:creator><dc:date> 2025-04-12</dc:date><dc:source>细胞</dc:source><dc:title>拟南芥单核图谱解码叶子的感应和营养分配</dc:title><dc:identifier>PMID：40220755</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.03.024</dc:identifier></item><item><title>工程TCR控制的模糊逻辑中的CAR T细胞增强了治疗特异性</title><link/>https://pubmed.ncbi.nlm.nih.gov/40220754/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>嵌合抗原受体（CAR）T细胞免疫疗法代表了血液恶性肿瘤治疗的突破，但较差的特异性限制了其对实体瘤的适用性。相比之下，携带T细胞受体（TCR）的天然T细胞可以区分表达新抗原的癌细胞和表达自我抗原的健康组织，但针对肿瘤的效力有限。我们使用高通量平台系统地评估了共表达TCR的影响... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>。 2025年4月10日：S0092-8674（25）00290-9。 doi：10.1016/j.cell.2025.03.017。在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">嵌合抗原受体（CAR）T细胞免疫疗法代表了血液恶性肿瘤治疗的突破，但较差的特异性限制了其对实体瘤的适用性。相比之下，携带T细胞受体（TCR）的天然T细胞可以区分表达新抗原的癌细胞和表达自我抗原的健康组织，但针对肿瘤的效力有限。我们使用高通量平台系统地评估了共表达TCR和汽车对同一汽车T细胞的影响。尽管强大的TCR抗原相互作用增强了汽车的激活，但弱TCR抗原相互作用会积极拮抗它们的激活。数学模型捕获了该TCR-CAR在CAR T细胞中的串扰，使我们能够设计靶向新抗原（HHAT <sup>L8F</sup> /p53 <sup>R175H</sup> ）的双重TCR /CAR T细胞（HHAT L8F /p53 R175H），人类上皮生长因子受体2（HER2），这些T细胞与这些T细胞相比，与人类的固定性质量相比，这些T细胞与抗抗癌的质量相比，将其与人类的固定性相比 模型。因此，利用受体之间的抑制性串扰，因此为设计更精确的癌症免疫疗法铺平了道路。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40220754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40220754</a> | doi： <a href=https://doi.org/10.1016/j.cell.2025.03.017>10.1016/j.cell.2025.03.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40220754</guid><pubDate> Sat, 12 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Taisuke Kondo</dc:creator><dc:creator> FrançoisXP Bourassa</dc:creator><dc:creator> Sooraj achar</dc:creator><dc:creator> Justyn Dusold</dc:creator><dc:creator> Pablofcéspedes</dc:creator><dc:creator> Makoto Ando</dc:creator><dc:creator> Alka Dwivedi</dc:creator><dc:creator> Josquin Moraly</dc:creator><dc:creator>克里斯托弗·基恩（Christopher Chien）</dc:creator><dc:creator> Saliha Majdoul</dc:creator><dc:creator>亚当·凯特（Adam L Kenet）</dc:creator><dc:creator>麦迪逊·瓦尔斯滕（Madison Wahlsten）</dc:creator><dc:creator>奥登·克瓦尔瓦（Audun Kvalvaag）</dc:creator><dc:creator>爱德华·詹金斯</dc:creator><dc:creator>Sanghyun P Kim</dc:creator><dc:creator>凯瑟琳·M·阿德（Catherine M Ade）</dc:creator><dc:creator> Zhiya yu</dc:creator><dc:creator> Guillaume Gaud</dc:creator><dc:creator>马可·达维拉（Marco Davila）</dc:creator><dc:creator>保罗·洛夫</dc:creator><dc:creator>詹姆斯·杨</dc:creator><dc:creator>迈克尔·达斯汀</dc:creator><dc:creator>格雷戈伊尔·阿尔坦 - 邦纳特</dc:creator><dc:creator>PaulFrançois</dc:creator><dc:creator> Naomi Taylor</dc:creator><dc:date> 2025-04-12</dc:date><dc:source>细胞</dc:source><dc:title>工程TCR控制的模糊逻辑中的CAR T细胞增强了治疗特异性</dc:title><dc:identifier>PMID：40220754</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.03.017</dc:identifier></item><item><title>细胞外呼吸是大肠杆菌中的潜在能量代谢</title><link/>https://pubmed.ncbi.nlm.nih.gov/40215961/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>不同的微生物利用氧化还原班车通过介导的细胞外电子转移（EET）将电子与环境交换，从而支持厌氧生存。尽管已将介导的EET用于生物催化分析已有数十年的历史，但有关这些氧化还原班的细胞中如何减少及其在细胞生物能学中的作用仍然存在的基本问题。在这里，我们整合了基因组编辑，电化学和系统生物学，以研究... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>。 2025年4月4日：S0092-8674（25）00289-2。 doi：10.1016/j.cell.2025.03.016。在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">不同的微生物利用氧化还原班车通过介导的细胞外电子转移（EET）将电子与环境交换，从而支持厌氧生存。尽管已将介导的EET用于生物催化分析已有数十年的历史，但有关这些氧化还原班的细胞中如何减少及其在细胞生物能学中的作用仍然存在的基本问题。在这里，我们整合了基因组编辑，电化学和系统生物学，以研究大肠杆菌中介导的EET的机制和生物能学，弹性已有二十多年了。在没有替代电子下沉的情况下，通过细胞质硝化酶NFSB NFSB和NFSA的2-羟基-1,4-萘醌（HNQ）的氧化还原循环使大肠杆菌在外细胞外电极上启用大肠杆菌呼吸。大肠杆菌还在外膜孔蛋白OMPC中表现出快速的遗传适应性，从而增强了HNQ介导的EET水平与生长结合。这项工作表明，大肠杆菌可以独立于经典的电子传输链和发酵而生长，从而揭示了一种潜在的新型厌氧能量代谢。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40215961/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40215961</a> | doi： <a href=https://doi.org/10.1016/j.cell.2025.03.016>10.1016/j.cell.2025.03.016</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40215961</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator>比基bapi kundu</dc:creator><dc:creator> Jayanth Krishnan</dc:creator><dc:creator>理查德·舒本（Richard Szubin）</dc:creator><dc:creator> Arjun Patel</dc:creator><dc:creator> Bernhard O Palsson</dc:creator><dc:creator>丹尼尔·齐林斯基（Daniel C Zielinski）</dc:creator><dc:creator> Caroline M Ajo-Franklin</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>细胞</dc:source><dc:title>细胞外呼吸是大肠杆菌中的潜在能量代谢</dc:title><dc:identifier>PMID：40215961</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.03.016</dc:identifier></item><item><title>校正：紫杉醇涂层的气球血管成形术与药物洗脱支架的治疗，用于治疗冠状动脉内再生毒：一项全面的，协作的，个体的患者数据荟萃分析，对10项随机临床试验（Daedalus研究）</title><link/> https://pubmed.ncbi.nlm.nih.gov/40215189/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 APR 11：EHAF217。 doi：10.1093/eurheartj/ehaf217。在线印刷。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40215189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40215189</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf217>10.1093/eurheartj/ehaf217</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40215189</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:date> 2025-04-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>校正：紫杉醇涂层的气球血管成形术与药物洗脱支架的治疗，用于治疗冠状动脉内再生毒：一项全面的，协作的，个体的患者数据荟萃分析，对10项随机临床试验（Daedalus研究）</dc:title><dc:identifier> PMID：40215189</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf217</dc:identifier></item><item><title>升主动脉和肺动脉的Rosai-Dorfman病模仿壁内血肿和肿块</title><link/>https://pubmed.ncbi.nlm.nih.gov/40214969/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 APR 11：EHAF250。 doi：10.1093/eurheartj/ehaf250。在线印刷。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40214969/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40214969</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf250>10.1093/eurheartj/ehaf250</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40214969</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Lijuan Qian</dc:creator><dc:creator> ji yu</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>升主动脉和肺动脉的Rosai-Dorfman病模仿壁内血肿和肿块</dc:title><dc:identifier>PMID：40214969</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf250</dc:identifier></item><item><title>醛固酮靶向疗法：耐药性高血压和慢性肾脏疾病的早期实施</title><link/>https://pubmed.ncbi.nlm.nih.gov/40214750/？ 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>耐药性高血压（TRH）经常与慢性肾脏疾病（CKD）共存，两种疾病的存在会增加心血管不良后果的风险。 TRH和CKD患者暴露了增强的醛固酮和矿物皮质激素受体的表达，促进心脏和肾脏组织的炎症和纤维化，这有助于心脏疾病的发展和进展。两者都能达到最佳血压（BP）控制和减轻...的风险</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 APR 11：EHAF225。 doi：10.1093/eurheartj/ehaf225。在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">耐药性高血压（TRH）经常与慢性肾脏疾病（CKD）共存，两种疾病的存在会增加心血管不良后果的风险。 TRH和CKD患者暴露了增强的醛固酮和矿物皮质激素受体的表达，促进心脏和肾脏组织的炎症和纤维化，这有助于心脏疾病的发展和进展。达到最佳血压（BP）控制和减轻醛固酮相关不良事件的风险都是TRH和CKD患者的管理中的基石。建议对TRH治疗矿物皮质激素受体拮抗剂（MRA）。迄今为止，已经在肾功能正常的人群中研究了效率。但是，高钾血症的潜在风险限制了MRA的使用，特别是在CKD患者中。非甾体类MRA和葡萄糖共转运蛋白-2抑制剂的肾功能下降减慢并显示出心脏益处。此外，醛固酮合酶抑制剂可能会成为TRH患者的治疗选择。 TRH主要的临床试验以评估BP的效果为中心；但是，仅降低BP可能不是足够的目标来防止患心脏疾病进展的风险。本文介绍了以醛固酮为目标的疗法在TRH和CKD治疗中的证据和潜在益处，并重新考虑了临床实践和试验设计中的治疗策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40214750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40214750</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf225>10.1093/eurheartj/ehaf225</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40214750</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Masatake Kobayashi</dc:creator><dc:creator>伯特拉姆·皮特（Bertram Pitt）</dc:creator><dc:creator> JoãoPedroFerreira</dc:creator><dc:creator>帕特里克·罗西尼尔（Patrick Rossignol）</dc:creator><dc:creator>尼古拉斯·吉尔德（Nicolas Girerd）</dc:creator><dc:creator> Faiez Zannad</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>醛固酮靶向疗法：耐药性高血压和慢性肾脏疾病的早期实施</dc:title><dc:identifier>PMID：40214750</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf225</dc:identifier></item><item><title>感染性心内膜炎：这需要一个团队</title><link/>https://pubmed.ncbi.nlm.nih.gov/40214743/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>感染性心内膜炎（IE）是一种相对罕见但威胁生命的全身感染，与高发病率和死亡率保持相关。 IE的流行病学已转变为涉及越来越多的具有心血管和其他类型的假体设备的老年患者，多种合并症通常需要侵袭性程序，越来越有毒的病原体，尤其是金黄色葡萄球菌，或者可能具有抗抗细菌抗性的抗性抗药性... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 APR 11：EHAF219。 doi：10.1093/eurheartj/ehaf219。在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">感染性心内膜炎（IE）是一种相对罕见但威胁生命的全身感染，与高发病率和死亡率保持相关。 IE的流行病学已经转变为越来越多的患有心血管和其他类型的人体假体设备的老年患者，多种合并症通常需要侵袭性程序，越来越有毒的病原体，尤其是金黄色葡萄球菌，或者可以携带抗生素抵抗的抗肌肉抗性，以及在许多领域中使用抗生素的药物。同时，诊断和治疗选择的进步导致了患者管理的复杂策略。尽管存在这些流行病学的转变，但临床试验很少见，大多数指导管理IE管理的证据源于专家共识或大型注册表的分析。因此，建议采用多学科的IE基于团队的方法作为护理标准。这篇评论的目的是探讨基于多学科的团队管理IE管理方法的理由。基于评估患者预后的多项投资，已提供了这种方法可能是有益的。此外，还强调了实施策略，团队方法的可行性和选择。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40214743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40214743</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf219>10.1093/eurheartj/ehaf219</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40214743</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator>劳伦斯·劳</dc:creator><dc:creator>拉里·巴德杜尔（Larry Baddour）</dc:creator><dc:creator> NúriaFernándezHidalgo</dc:creator><dc:creator>托马斯·D兄弟</dc:creator><dc:creator>威廉KF Kong</dc:creator><dc:creator>迈克尔·鲍格（Michael a Borger）</dc:creator><dc:creator> Xavier Duval</dc:creator><dc:creator>克里斯托夫tribouille</dc:creator><dc:creator> Jean-Francois Obadia</dc:creator><dc:creator> Mehrdad Golian</dc:creator><dc:creator> Vicente F Corrales-Medina</dc:creator><dc:creator> Francois Auclair</dc:creator><dc:creator> Mikael Mazighi</dc:creator><dc:creator>关隆</dc:creator><dc:creator>Bernard Prendergast</dc:creator><dc:creator>吉尔伯特·哈比卜</dc:creator><dc:creator>Fraser D Rubens</dc:creator><dc:creator> David Messika-Zeitoun</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>感染性心内膜炎：这需要一个团队</dc:title><dc:identifier>PMID：40214743</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf219</dc:identifier></item><item><title>大辩论：血浆甘油三酸酯是动脉粥样硬化心血管疾病的重要因果因素和治疗靶点</title><link/>https://pubmed.ncbi.nlm.nih.gov/40214301/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 APR 11：EHAF214。 doi：10.1093/eurheartj/ehaf214。在线印刷。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40214301/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40214301</a> | doi： <a href=https://doi.org/10.1093/eurheartj/ehaf214>10.1093/eurheartj/ehaf214</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40214301</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> JanBorén</dc:creator><dc:creator>克里斯·帕卡德（Chris Packard）</dc:creator><dc:creator> BørgeGNordestgaard</dc:creator><dc:creator> Alberico L Catapano</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>大辩论：血浆甘油三酸酯是动脉粥样硬化心血管疾病的重要因果因素和治疗靶点</dc:title><dc:identifier>PMID：40214301</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf214</dc:identifier></item><item><title>心脏具有内在的生酮能力，可介导NAD &lt;sup>;+&lt;/sup>; HFPEF中的治疗</title><link/>https://pubmed.ncbi.nlm.nih.gov/40211954/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign=pubmed-2&amp;utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLQC-＆FC = 20230708114047＆ff = 20250415061254＆v = 2.18.0.post9+e462414<description>结论：典型的生酮酶HMGCS2通过恢复正常的脂质代谢和线粒体功能，介导HFPEF中烟酰胺腺苷二核苷酸复制的氧化形式的治疗作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res。 2025年4月11日。doi：10.1161/circresaha.124.325550。在线印刷。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has overtaken heart failure with reduced ejection fraction as the leading type of heart failure globally and is marked by high morbidity and mortality rates, yet with only a single approved pharmacotherapy: SGLT2i (sodium-glucose co-transporter 2 inhibitor). A prevailing theory for the mechanism underlying SGLT2i is nutrient deprivation signaling, of which ketogenesis is a hallmark. However, it is unclear whether the canonical ketogenic enzyme, HMGCS2 (3-hydroxy-3-methylglutaryl-coenzyme A synthase 2), plays any cardiac role in HFpEF pathogenesis or therapeutic response. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We used human myocardium, human HFpEF and heart failure with reduced ejection fraction transcardiac blood sampling, an established murine model of HFpEF, ex vivo Langendorff perfusion, stable isotope tracing in isolated cardiomyocytes, targeted metabolomics, proteomics, lipidomics, and a novel cardiomyocyte-specific conditional HMGCS2-deficient model that we generated. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We demonstrate, for the first time, the intrinsic capacity of the human heart to produce ketones via HMGCS2. We found that increased acetylation of HMGCS2 led to a decrease in the enzyme&#39;s specific activity. However, this was overcome by an increase in the steady-state levels of protein. Oxidized form of nicotinamide adenine dinucleotide repletion restored HMGCS2 function via deacetylation, increased fatty acid oxidation, and rescued cardiac function in HFpEF. Critically, using a conditional, cardiomyocyte-specific HMGCS2 knockdown murine model, we revealed that the oxidized form of nicotinamide adenine dinucleotide is unable to rescue HFpEF in the absence of cardiomyocyte HMGCS2. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The canonical ketogenic enzyme, HMGCS2, mediates the therapeutic effects of the oxidized form of nicotinamide adenine dinucleotide repletion in HFpEF by restoring normal lipid metabolism and mitochondrial function.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40211954/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40211954</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.124.325550>10.1161/CIRCRESAHA.124.325550</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40211954</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Yen Chin Koay</dc:creator><dc:creator> Bailey McIntosh</dc:creator><dc:creator> Yann Huey Ng</dc:creator><dc:creator> Yang Cao</dc:creator><dc:creator> XiaoSuo Wang</dc:creator><dc:creator> Yanchuang Han</dc:creator><dc:creator> Saki Tomita</dc:creator><dc:creator> Angela Yu Bai</dc:creator><dc:creator> Benjamin Hunter</dc:creator><dc:creator> Ashish Misra</dc:creator><dc:creator> Christopher M Loughrey</dc:creator><dc:creator> Paul G Bannon</dc:creator><dc:creator> Sean Lal</dc:creator><dc:creator> Aldons J Lusis</dc:creator><dc:creator> David M Kaye</dc:creator><dc:creator> Mark Larance</dc:creator><dc:creator> John F O&#39;Sullivan</dc:creator><dc:date> 2025-04-11</dc:date><dc:source> Circulation research</dc:source><dc:title> Heart Has Intrinsic Ketogenic Capacity that Mediates NAD&lt;sup>;+&lt;/sup>; Therapy in HFpEF</dc:title><dc:identifier> pmid:40211954</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.124.325550</dc:identifier></item><item><title> Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF</title><link/> https://pubmed.ncbi.nlm.nih.gov/40211947/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250415061254&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Targeting SETD2 might prevent lipotoxic injury in cHFpEF. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2025 Apr 11. doi: 10.1161/CIRCRESAHA.124.325310. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Cardiometabolic heart failure with preserved ejection fraction (cHFpEF) is a highly prevalent and deadly condition. Histone 3 trimethylation at lysine 36 (H3k36me3)-a chromatin signature induced by the histone methyltransferase SETD2 (SET domain containing 2)-correlates with changes in gene expression in human failing hearts; however, its role remains poorly understood. This study investigates the role of SETD2 in cHFpEF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Chromatin immunoprecipitation sequencing and RNA sequencing were used to investigate H3k36me3-related transcriptional regulation. Mice with cardiomyocyte-specific deletion of SETD2 (c-SETD2 <sup>-/-</sup> ) were generated and subjected to high-fat diet feeding and L-NAME treatment for 15 weeks to induce cHFpEF. Cardiac function and exercise tolerance were assessed by echocardiography and treadmill exhaustion test. A selective pharmacological inhibitor of SETD2, EZM0414, was also tested in cHFpEF mice. Mechanistic experiments were performed in cultured cardiomyocytes exposed to palmitic acid. SETD2 signaling and the effects of EZM0414 were also investigated in cardiomyocytes from patients with cHFpEF and control donors. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: SETD2 was upregulated in cHFpEF mouse hearts, and its chromatin mark H3k36me3 was involved in lipid metabolism and highly enriched on the promoter of the <i>Srebf1</i> gene, encoding for SREBP1 (sterol regulatory binding protein 1). SETD2 activation in cHFpEF led to SREBP1 upregulation, triglyceride accumulation, and lipotoxic damage. Of note, cardiomyocyte-specific deletion of SETD2 in mice prevented heart failure with preserved ejection fraction-related hypertrophy, diastolic dysfunction, and lung congestion while improving exercise tolerance. SETD2 deletion blunted H3K36me3 enrichment on <i>Srebf1</i> promoter, thus leading to a marked rewiring of the cardiac lipidome and restoration of autophagic flux. In vivo treatment with the SETD2 inhibitor EZM0414 recapitulated the effects of SETD2 deletion. Silencing of SETD2 in palmitic acid-treated cardiomyocytes prevented SREBP1 upregulation, whereas SETD2 overexpression mirrored lipotoxic damage. Finally, SETD2 was upregulated in left ventricle specimens from patients with cHFpEF while EZM0414 attenuated cardiomyocyte stiffness. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Targeting SETD2 might prevent lipotoxic injury in cHFpEF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40211947/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40211947</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.124.325310>10.1161/CIRCRESAHA.124.325310</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40211947</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Sarah Costantino</dc:creator><dc:creator> Shafeeq A Mohammed</dc:creator><dc:creator> Samuele Ambrosini</dc:creator><dc:creator> Marialucia Telesca</dc:creator><dc:creator> Alessandro Mengozzi</dc:creator><dc:creator> Kaivalya Walavalkar</dc:creator><dc:creator> Era Gorica</dc:creator><dc:creator> Melissa Herwig</dc:creator><dc:creator> Loek van Heerebeek</dc:creator><dc:creator> Junyan Xia</dc:creator><dc:creator> Gergely Karsai</dc:creator><dc:creator> Thorsten Hornemann</dc:creator><dc:creator> Omer Dzemali</dc:creator><dc:creator> Raffaella Santoro</dc:creator><dc:creator> Qian Li</dc:creator><dc:creator> Frank Ruschitzka</dc:creator><dc:creator> Nazha Hamdani</dc:creator><dc:creator> Francesco Paneni</dc:creator><dc:date> 2025-04-11</dc:date><dc:source> Circulation research</dc:source><dc:title> Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF</dc:title><dc:identifier> pmid:40211947</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.124.325310</dc:identifier></item><item><title> Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy</title><link/> https://pubmed.ncbi.nlm.nih.gov/40211944/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250415061254&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by DSC2 loss of function, supported by human and mouse data. Loss of Myl7 contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. Dsc2 mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Apr 11. doi: 10.1161/CIRCULATIONAHA.124.072340. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Whole-exome sequencing identified a novel <i>DSC2</i> sequence variation causing autosomal recessive ARVC in a Chinese family with consanguineous marriage. Mouse models with <i>Dsc2</i> sequence variation knock-in and constitutive knock-out were generated and analyzed using echocardiography and histology. Transcriptomic and biochemical analyses were conducted to explore ARVC mechanisms. <i>Dsc2</i> mRNA delivered by intracardiac or transcoronary injection was assessed as a treatment for ARVC in <i>Dsc2</i> knock-out mice. In addition, effects of <i>Dsc2</i> mRNA were examined in a transverse aortic constriction mouse model with noninherited right ventricular systolic dysfunction. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: <i>Dsc2</i> -deficient mice exhibited right ventricular dilation and dysfunction, mimicking human disease. Transcriptomic analysis identified <i>Myl7</i> as the most downregulated gene in the right ventricles of <i>Dsc2</i> -deficient mice, and its restoration by adeno-associated virus 9 rescued heart function. <i>Dsc2</i> mRNA delivery, with or without lipid nanoparticle encapsulation, normalized heart size and function in <i>Dsc2</i> -deficient mice. Reduced <i>DSC2</i> and <i>MLC2a</i> expression was also noted in patients with noninherited dilated cardiomyopathy and in mice with transverse aortic constriction. A single dose of mRNA provided therapeutic effects lasting 2 to 3 months before declining. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by <i>DSC2</i> loss of function, supported by human and mouse data. Loss of <i>Myl7</i> contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. <i>Dsc2</i> mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40211944/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250415061254&v=2.18.0.post9+e462414">40211944</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072340>10.1161/CIRCULATIONAHA.124.072340</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40211944</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Yan Zou</dc:creator><dc:creator> Jing Lu</dc:creator><dc:creator> Zhipeng Lian</dc:creator><dc:creator> Jianguo Jia</dc:creator><dc:creator> Juan Shen</dc:creator><dc:creator> Qianhe Li</dc:creator><dc:creator> Jennifer Ming Jen Wong</dc:creator><dc:creator> Kejia Jin</dc:creator><dc:creator> Wendi Yan</dc:creator><dc:creator> Xinyue Ren</dc:creator><dc:creator> Yang Zhang</dc:creator><dc:creator> Chenxing Huang</dc:creator><dc:creator> Huanjie Yang</dc:creator><dc:creator> Feng Huang</dc:creator><dc:creator> Jun Li</dc:creator><dc:creator> Junyu Zhai</dc:creator><dc:creator> Yamei Xu</dc:creator><dc:creator> Xialian Xu</dc:creator><dc:creator> Hang Yu</dc:creator><dc:creator> Yi Jin</dc:creator><dc:creator> Hui Gong</dc:creator><dc:creator> Jinzhong Lin</dc:creator><dc:creator> Junbo Ge</dc:creator><dc:creator> Yuxiang Dai</dc:creator><dc:date> 2025-04-11</dc:date><dc:source> Circulation</dc:source><dc:title> Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy</dc:title><dc:identifier> pmid:40211944</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.072340</dc:identifier></item></channel></rss>